Clinical trials: Severe Septic Syndrome
COVID-19
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS)…
- Trial name
- NCT04351243
- Testing
- Gimsilumab
- Where
- 33 sites in United States
- Volunteers
- 227 people
- Sponsor
- Kinevant Sciences GmbH
Sepsis, Severe Sepsis
Endothelium in Severe Sepsis
The overall hypotheses of this project is that severe sepsis is associated with endothelial dysfunction; that endothelial dysfunction, in turn, is predictive of subsequent organ failure and death; and that protocolized…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- NCT00793442
- Testing
- Blood Collection and Assays
- Where
- 7 sites in United States
- Volunteers
- 910 people
- Sponsor
- Beth Israel Deaconess Medical Center
Covid19, Sepsis
Blood Markers for Identifying & Investigating Infection With COVID19 & Sepsis in Children.
Corona Virus Disease or COVID-19 is caused by SARS-CoV-2 virus. There have been reports of serious COVID-19 illness in children. In addition it has been linked to clusters of children presenting with high fevers and inflammation.
- Trial name
- pSeP (NCT04904523)
- Testing
- Diagnostic Test:Blood test
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- Cardiff University
Sepsis Syndrome, Sepsis
Mitochondrial DNA as a Biomarker of Sepsis Severity
Mitochondria are organelles (a specialized subunit of a cell) responsible for providing cells with energy. For reasons not yet understood, mitochondria will release their DNA into blood in response to cellular injury or cell…
- Conditions
- Sepsis Syndrome, Sepsis, Severe Sepsis, Septic Shock
- Trial name
- MBOSS (NCT03077672)
- Where
- 2 sites in United States
- Volunteers
- 1,304 people
- Sponsor
- Weill Medical College of Cornell University
Severe Sepsis, Septic Shock
Cerebrovascular Autoregulation in Sepsis, Influence of Renal Replacement Therapy
The cerebrovascular autoregulation is impaired in patients with severe sepsis and septic shock. A continuous veno-venous hemodialysis may improve impaired cerebrovascular autoregulation.
- Trial name
- SepsAR2 (NCT01926301)
- Testing
- continuous veno-venous hemodialysis
- Where
- Germany
- Sponsor
- Johannes Gutenberg University Mainz
Critical Illness, Severe Sepsis
Near Infrared Spectroscopy (NIRS) in Severe Sepsis
The purpose of this study is to evaluate the usefulness of an optimization of muscle perfusion and oxygenation, as assessed by the NIRS technique, in critically ill patients with sepsis.
- Trial name
- OTO-STS (NCT00167596)
- Testing
- Near Infrared Spectroscopy, conventional
- Where
- 7 sites in France, Germany and 2 more
- Volunteers
- 103 people
- Sponsor
- University of Versailles
Acute Respiratory Tract Infection, Acute Respiratory Insufficiency
An Open Randomized Study of Dalargin Efectiveness in Combination With Leitragin Drug in Patients With Severe and Critical Manifestations of SARS-COVID-19
The purpose of the study is to evaluate an effectiveness of the drug Dalargin in combination with Leitragin for the prevention and treatment of severe pulmonary complications symptoms associated with severe and critical…
- Conditions
- Acute Respiratory Tract Infection, Acute Respiratory Insufficiency, Pneumonia, Septic Shock
- Trial name
- NCT04346693
- Testing
- Standard therapy recommended by the Ministry of Health of the Russian Federation., Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin intramuscular injection, Standard therapy recommended by the Ministry of Health of the Russian Federation and Leitragin inhalation
- Where
- Russia
- Volunteers
- 320 people
- Sponsor
- Burnasyan Federal Medical Biophysical Center
Septic Shock, Endotoxemia
Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19
Prospective, observational, clinical investigation of PMX cartridge use in COVID 19 patients with septic shock
- Conditions
- Septic Shock, Endotoxemia, COVID, Corona Virus Infection
- Trial name
- NCT04352985
- Testing
- Toraymyxin PMX-20R (PMX Cartridge)
- Where
- 3 sites in United States
- Sponsor
- Spectral Diagnostics (US) Inc.
Sepsis Syndromes
Exercise in Critically Ill Patients With Sepsis
This study will investigate whether early exercise in critically ill patients will decrease inflammatory markers, increase pro-inflammatory markers and prevent loss of muscle mass.
- Trial name
- NCT01364909
- Testing
- Exercise, Usual practice
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- The University of Queensland
Severe Sepsis
4G/5G Polymorphism of Plasminogen Activator Inhibitor-1 Gene and Disseminated Intravascular Coagulation in Severe Sepsis and Septic Shock
Data on 4G/5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene are limited in Asian patients with sepsis. Therefore, the investigators aim to prospectively investigate the incidence of 4G/5G polymorphism and its…
- Trial name
- NCT01211899
- Volunteers
- 160 people
- Sponsor
- Hallym University Medical Center
Severe Sepsis, Septic Shock
Outcomes of Severe Sepsis Patients in Surgical Intensive Care Units
Retrospective review of the outcomes of severe sepsis patients in Surgical Intensive Care Unit of National Taiwan University Hospital from January 1, 2009 to December 31, 2011.
- Trial name
- NCT01919138
- Where
- Taiwan
- Volunteers
- 762 people
- Sponsor
- National Taiwan University Hospital
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Covid19 Pneumonia
The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation
Title: The use of Tocilizumab in the management of patients who have severe COVID-19 with suspected pulmonary hyperinflammation.
- Trial name
- NCT04377750
- Testing
- Tocilizumab
- Where
- 4 sites in Israel
- Volunteers
- 500 people
- Sponsor
- Hadassah Medical Organization
Severe Sepsis, Septic Shock
Procalcitonin Monitoring Sepsis Study
The purpose of this study is to investigate the relationship between a procalcitonin decrease over 72 hours and outcome in patients who have severe sepsis or septic shock.
- Trial name
- MOSES (NCT01523717)
- Where
- 13 sites in United States
- Volunteers
- 858 people
- Sponsor
- Brahms AG
Sepsis
GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
The primary objective is to estimate the size of the GR270773 treatment effect on 28-day all-cause mortality for two doses of GR270773 versus placebo in adult subjects with suspected or confirmed Gram-negative severe sepsis.
- Trial name
- NCT00089986
- Testing
- Intravenous GR270773- Phospholipid Emulsion
- Where
- 390 sites in United States, Argentina and 32 more
- Volunteers
- 1,415 people
- Sponsor
- GlaxoSmithKline
Severe Sepsis
Volume Therapy With Crystalloids and Colloids and Hemodynamic Monitoring in Patients With Severe Sepsis
The primary alternative hypothesis is that less time (minutes) is required, to achieve the initial hemodynamic stabilization, with Volulyte® compared to Jonosteril®.
- Trial name
- VOMOSEP (NCT02587078)
- Testing
- Volulyte, Jonosteril
- Sponsor
- Wuerzburg University Hospital
Coronavirus Disease 2019 (COVID-19) Pneumonia
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19
The primary objective of this study is to assess whether the use of lenzilumab in addition to current standard of care can alleviate the immune-mediated cytokine release syndrome (CRS) and improve ventilator-free survival in…
- Trial name
- NCT04351152
- Testing
- Lenzilumab, Standard of Care
- Where
- 29 sites in United States, Brazil
- Volunteers
- 520 people
- Sponsor
- Humanigen, Inc.
Sepsis, Severe
Immune Profile of Patients With Sepsis
The immune response can acquire different profiles (proinflammatory and anti-inflammatory response) depending on the activating agent.The objective of this study is to compare the immunological profile in patients with severe…
- Trial name
- IPSEPSIS (NCT04163705)
- Testing
- blood sample collection
- Volunteers
- 40 people
- Sponsor
- Hospital El Cruce
Severe Sepsis, Septic Shock
Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP Trial)
The purpose of this trial is to determine the influence of colloid versus crystalloid volume resuscitation and of intensive vs conventional insulin therapy on morbidity and mortality of patients with severe sepsis and septic…
- Trial name
- NCT00135473
- Testing
- 10% Hemohes® (10% Hydroxyethyl starch), Sterofundin® (Ringer lactate solution), Actrapid® (Insulin)
- Where
- 16 sites in Germany
- Volunteers
- 600 people
- Sponsor
- SepNet - Critical Care Trials Group
Sepsis, Septic Shock
Investigation of the Role of Brain Natriuretic Peptide and Lactate in Early Goal-directed Therapy for Patients With Severe Sepsis and Septic Shock
B-type natriuretic peptide (BNP) is a cardiac neurohormone which rapidly released by the ventricle in response to myocardial stretch.
- Trial name
- NCT01539551
- Testing
- check BNP and lactate
- Where
- Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital